These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 27224743)

  • 1. Proton pump inhibitors and osteoporosis.
    Andersen BN; Johansen PB; Abrahamsen B
    Curr Opin Rheumatol; 2016 Jul; 28(4):420-5. PubMed ID: 27224743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures.
    Fournier MR; Targownik LE; Leslie WD
    Maturitas; 2009 Sep; 64(1):9-13. PubMed ID: 19674854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
    Lin SM; Yang SH; Liang CC; Huang HK
    Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of long-term proton pump inhibitors on bone mineral density.
    Romdhane H; Ayadi S; Elleuch N; Abdelghani K
    Tunis Med; 2018 Mar; 96(3):193-197. PubMed ID: 30325487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do FDA label changes work? Assessment of the 2010 class label change for proton pump inhibitors using the Sentinel System's analytic tools.
    Sobel RE; Bate A; Marshall J; Haynes K; Selvam N; Nair V; Daniel G; Brown JS; Reynolds RF
    Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):332-339. PubMed ID: 29392851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study.
    Freedberg DE; Haynes K; Denburg MR; Zemel BS; Leonard MB; Abrams JA; Yang YX
    Osteoporos Int; 2015 Oct; 26(10):2501-7. PubMed ID: 25986385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship among proton pump inhibitors, bone disease and fracture.
    Targownik LE; Leslie WD
    Expert Opin Drug Saf; 2011 Nov; 10(6):901-12. PubMed ID: 21599546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term proton pump inhibitor therapy and osteoporosis. Is there a real danger?].
    Maléth J; Hegyi P
    Orv Hetil; 2013 Jun; 154(26):1005-9. PubMed ID: 23800385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of proton pump-inhibiting drugs on mineral metabolism.
    Insogna KL
    Am J Gastroenterol; 2009 Mar; 104 Suppl 2():S2-4. PubMed ID: 19262542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescribing of anti-osteoporotic therapies following the use of proton pump inhibitors in general practice.
    McGowan B; Bennett K; Barry M
    Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):763-9. PubMed ID: 20582909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study.
    Abtahi S; Driessen JHM; Burden AM; Souverein PC; van den Bergh JP; van Staa TP; Boonen A; de Vries F
    Ann Rheum Dis; 2021 Apr; 80(4):423-431. PubMed ID: 33310727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between proton pump inhibitors and hyperparathyroidism: a potential mechanism for increased fracture-results of a large observational cohort study.
    Fitzpatrick D; Lannon R; Laird E; Ward M; Hoey L; Hughes CF; Strain JJ; Cunningham C; McNulty H; Molloy AM; McCarroll K
    Osteoporos Int; 2023 Nov; 34(11):1917-1926. PubMed ID: 37530847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.
    Targownik LE; Lix LM; Leung S; Leslie WD
    Gastroenterology; 2010 Mar; 138(3):896-904. PubMed ID: 19931262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study.
    van der Hoorn MMC; Tett SE; de Vries OJ; Dobson AJ; Peeters GMEEG
    Bone; 2015 Dec; 81():675-682. PubMed ID: 26319499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic proton pump inihibitor therapy and calcium metabolism.
    Yang YX
    Curr Gastroenterol Rep; 2012 Dec; 14(6):473-9. PubMed ID: 23054811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals.
    Maggio M; Lauretani F; Ceda GP; De Vita F; Bondi G; Corsonello A; Cattabiani C; Lattanzio F; Ruggiero C; Nouvenne A; Meschi T; Bandinelli S; Ferrucci L
    Bone; 2013 Dec; 57(2):437-42. PubMed ID: 24076021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study.
    Fraser LA; Leslie WD; Targownik LE; Papaioannou A; Adachi JD;
    Osteoporos Int; 2013 Apr; 24(4):1161-8. PubMed ID: 22890365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between long-term proton pump inhibitor therapy and skeletal frailty.
    Lau AN; Tomizza M; Wong-Pack M; Papaioannou A; Adachi JD
    Endocrine; 2015 Aug; 49(3):606-10. PubMed ID: 25948072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term use of proton pump inhibitors adversely affects minerals and vitamin metabolism, bone turnover, bone mass, and bone strength.
    Hussain MS; Mazumder T
    J Basic Clin Physiol Pharmacol; 2022 Sep; 33(5):567-579. PubMed ID: 34687598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.
    Freedberg DE; Kim LS; Yang YX
    Gastroenterology; 2017 Mar; 152(4):706-715. PubMed ID: 28257716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.